Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial

Rana, Huma Q.; Stopfer, Jill E.; Weitz, Michelle; Kipnis, Lindsay; Koeller, Diane R.; Culver, Samantha; Mercado, Joanna; Gelman, Rebecca Sue; Underhill-Blazey, Meghan; McGregor, Bradley A.; Sweeney, Christopher J.; Petrucelli, Nancie; Kokenakes, Courtney; Pirzadeh-Miller, Sara; Reys, Brian; Frazier, Arthur; Knechtl, Andrew; Fateh, Salman; Vatnick, Donna Rachel; Silver, Rebecca; Kilbridge, Kerry E.; Pomerantz, Mark M.; Wei, Xiao X.; Choudhury, Atish D.; Sonpavde, Guru P.; Kozyreva, Olga; Lathan, Christopher; Horton, Carrie; Dolinsky, Jill S.; Heath, Elisabeth I.; Ross, Theodora Suzanne; Courtney, Kevin Dale; Garber, Judy E.; Taplin, Mary-Ellen

doi:10.1200/op.23.00007

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, alternate delivery models for genetics care delivery are needed. The ProGEN randomized clinical trial showed no differences in uptake and completion of genetic testing interventions between video‐based and in‐person genetic counseling, 61 the EMPOWER study showed males prefer pre‐test video based counseling, 62 and the GENTleMEN study showed high genetic testing rates using internet‐based testing platforms 63 . Despite these successes, low rates of genetic testing uptake remain in self‐identified Black and Asian populations, and additional efforts are needed to increase genetic testing rates in these populations.…”

Section: Reducing Prostate Cancer Morbidity and Mortality With Geneticsmentioning

confidence: 99%

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira,

Kamran,

Jamaspishvili

et al. 2024

The Prostate

View full text Add to dashboard Cite

IntroductionThe 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.MethodsThe 2023 marked the 10th Annual CHPCA Meeting, a discussion‐oriented scientific think‐tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.ResultsThe central topic areas covered at the meeting included: targeting transcription factor neo‐enhancesomes in cancer, AR as a pro‐differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence‐driven precision medicine.DiscussionThis article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.

show abstract

Section: Reducing Prostate Cancer Morbidity and Mortality With Geneticsmentioning

confidence: 99%

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira,

Kamran,

Jamaspishvili

et al. 2024

The Prostate

View full text Add to dashboard Cite

show abstract

Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer

Pederson,

Narod

2024

BJC Rep

View full text Add to dashboard Cite

It is thirty years since the BRCA1 and BRCA2 genes were discovered and genetic testing for BRCA1 and BRCA2 was introduced. Despite increasing awareness of the genetic basis of cancer and our evolving knowledge of effective means of prevention, screening, and treatment for hereditary breast and ovarian cancers, genetic testing is underutilized, and most mutation carriers remain unidentified. In this commentary, we explore possible reasons for why this might be so. Our focus is on factors that may influence or deter a patient from pursuing testing, rather than discussing the implications of receiving a positive test result. Issues of concern include an inadequate number of genetic counselors, restrictive (and conflicting) eligibility criteria for testing, the cost of the test, health insurance coverage, fear of future insurance discrimination, privacy issues, lack of familiarity with the testing process in primary care and gaps in both patient and provider knowledge about the impact and the value of testing. We discuss how these factors may lead to the underutilization of genetic testing in North America and throughout the world and discuss alternative models of genetic healthcare delivery. We have invited leaders in cancer genetic from around the world to tell us what they think are the barriers to testing in their host countries.

show abstract

Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial

Abstract: In this large, multisite RCT, pretest video education shows promise for men with prostate cancer.

Cited by 2 publications

References 49 publications

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer

Contact Info

Product

Resources

About